Information  X 
Enter a valid email address

Angel Biotechnology (ABH)

  Print      Mail a friend

Thursday 17 December, 2009

Angel Biotechnology

GMP manufacturing contract fo

RNS Number : 2989E
Angel Biotechnology Holdings Plc
17 December 2009
 



 


17th  December 2009


ANGEL BIOTECHNOLOGY HOLDINGS PLC 

("Angel" or "the Company")

 


Angel announces award of GMP manufacturing contract for Phase II trial


Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract manufacturer, is pleased to announce the signing of a contract with a UK based biotechnology company for GMP manufacturing of an advanced biologic for Phase II clinical trials. The contract, valued at circa £0.5 million, is due to complete in June 2010.


Gordon Sherriff, COO of Angel Biotechnology plc said "We are delighted to have been awarded this contract. This further demonstrates that Angel's service offering fits well with the needs of biotech companies developing advanced biologics Angel's experience of working with innovative live biologics products has enabled us to provide a high quality and cost effective solution for this company's GMP manufacturing requirements for its Phase II clinical trials."


For further information, please call:

Angel Biotechnology Holdings plc

Tel: +44 (0) 131 445 6077

Gordon Sherriff - COO

Tel: +44 (0) 7951 057016



Grant Thornton Corporate Finance

Tel: +44 (0)20 7383 5100

Philip Secrett/Colin Aaronson




Matrix Corporate Capital LLP

Tel +44 (0) 20 3206 7000 

Steve Cox/Steve Waterman  




About Angel Biotechnology Holdings plc

Angel Biotechnology Holdings plc is a biomanufacturing company offering process development services and GMP manufacturing for advanced biologics, supporting biotechnology and pharmaceutical companies worldwide.  Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.  Angel specializes in the provision of advanced biologics; these include autologous and allogeneic cell therapy products, stem cells, cellular vaccines, specific purified natural and recombinant proteins and bacteriophage.  Angel is managed by a team with wide ranging experience in biopharmaceutical manufacture, gained in companies such as Glaxo, Johnson and Johnson, Serologicals Inc., PPL Therapeutics and Intercell Ag.

Angel was admitted to trading on AIM in November 2005. More information about the Company can be found at www.angelbio.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCILFIFFILDLIA

a d v e r t i s e m e n t